Project description DEENESFRITPL Diagnosing 301 allergies at a time Allergies affect more than 1 billion people globally (150 million of these in Europe) but identifying allergens is notoriously difficult, slow and expensive. The socioeconomic burden on workplaces and families is high. This project revolves around the FABER test, which can diagnose 301 allergens at a time and accommodate newly-discovered triggers as well. Using nanotechnology, the FABER test can also produce results faster and more accurately than conventional methods, at a reasonable price. This personalised test will also be disseminated through the FABER-Net, a local-level network of labs sharing expertise globally. Show the project objective Hide the project objective Objective Allergies are the most common chronic disease: with >1B people affected globally, of which >150M in Europe, today allergies are a worldwide epidemic. Besides clinical symptoms such as rhinitis, asthma and atopic eczema, allergies cause distress in those affected, who live in fear of an asthma attack, anaphylactic shock, or death from an allergic reaction. In addition, allergies have high costs for businesses and society: in the EU, work absenteeism of allergic patients costs €55-151B/year, while families with one allergic child or adult spend an extra €3,900-8,100/year. A high-quality and reliable allergy diagnosis is essential to identify the best treatment option for allergic patients and improve their health, and also to reduce costs. Today there are >3000 molecules known to cause allergies, but current methods for diagnosis are not able to test a high number of allergens, at a reasonable price and in a short time; also, most of them are invasive and present some risks for the patients. On top of this, every year new allergens are discovered, but they can’t be included in diagnostic tests for technical and economic reasons. To overcome these limitations ADL has created the FABER test: a multiplex system for allergy diagnosis that can test 301 allergens at the time - the highest number currently available. This is a flexible system based on nanotechnology in which the number of allergens can be increased when new ones are available. ADL aims to expand in Europe and then worldwide the network of labs that provide FABER allergy diagnosis at the most local level and with ADL’s highest testing quality. Thanks to this network (FABER-Net), the FABER test will be available for many patients suffering from allergies, who will have a more informative diagnosis, which in turn will allow a more personalized and effective treatment. This will improve the patients’ health and reduce their absenteeism from work, thus cutting costs in healthcare and associated with work absence Fields of science medical and health sciencesclinical medicinepneumologyasthmamedical and health sciencesclinical medicinedermatologyengineering and technologynanotechnologymedical and health sciencesclinical medicineallergology Programme(s) H2020-EU.2.3. - INDUSTRIAL LEADERSHIP - Innovation In SMEs Main Programme H2020-EU.3. - PRIORITY 'Societal challenges H2020-EU.2.1. - INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies Topic(s) EIC-SMEInst-2018-2020 - SME instrument Call for proposal H2020-EIC-SMEInst-2018-2020 See other projects for this call Sub call H2020-SMEInst-2018-2020-1 Funding Scheme SME-1 - SME instrument phase 1 Coordinator ALLERGY DATA LABORATORIES SRL Net EU contribution € 50 000,00 Address Via nino bixio 11 04100 Latina lt Italy See on map Region Centro (IT) Lazio Latina Activity type Private for-profit entities (excluding Higher or Secondary Education Establishments) Links Contact the organisation Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window Other funding € 21 429,00
